添加雄激素可改善老年急性髓系白血病患者的生存:一项GOELAMS研究
该多中心III期随机开放标签试验纳入330例60岁及以上急性髓系白血病患者,比较维持治疗中加用诺乙雄龙与不加用的疗效。结果显示,在诱导后1年仍处于缓解的患者中,诺乙雄龙显著改善无病生存、无事件生存和总生存,且未增加毒性。
要点
- 在诱导后1年仍处于缓解的老年AML患者中,诺乙雄龙维持治疗显著改善生存。
- A组与B组5年无病生存分别为31.2%和16.2%,无事件生存分别为21.5%和12.9%,总生存分别为26.3%和17.2%。
- 仅基线白细胞>30×10^9/L的患者未从诺乙雄龙获益。
核心结论
- 诺乙雄龙维持治疗显著改善老年急性髓系白血病患者的生存,且未增加毒性。
研究设计与样本
- 多中心、III期、随机、开放标签试验,共纳入330例60岁及以上初发或继发于化疗或放疗的急性髓系白血病患者。
- 诱导方案包括去甲氧柔红霉素8 mg/m2第1至5天、阿糖胞苷100 mg/m2第1至7天、洛莫司汀200 mg/m2第1天。
- 完全缓解或部分缓解的患者接受6个再诱导疗程,交替使用去甲氧柔红霉素8 mg/m2第1天、阿糖胞苷100 mg/m2第1至5天以及甲氨蝶呤和巯嘌呤方案。
- 患者随机接受诺乙雄龙10或20 mg/天(根据体重)或不接受诺乙雄龙,维持治疗2年。
- 主要终点为意向治疗无病生存;次要终点为无事件生存、总生存和安全性。
主要发现
- 随机分配A组165例接受诺乙雄龙,B组165例不接受诺乙雄龙。
- 247例(76%)达到完全缓解或部分缓解。
- Schoenfeld时间依赖模型显示,诺乙雄龙显著改善诱导后1年仍处于缓解患者的生存。
- A组与B组5年无病生存分别为31.2%和16.2%,无事件生存分别为21.5%和12.9%,总生存分别为26.3%和17.2%。
- 诺乙雄龙改善结局与所有预后因素无关;仅基线白细胞>30×10^9/L的患者未从诺乙雄龙获益。
关键数值与推荐
- 诺乙雄龙用法为10或20 mg/天(根据体重),维持治疗2年。
- 主要终点为意向治疗无病生存。
临床怎么用
- 对于60岁及以上急性髓系白血病患者,在诱导后1年仍处于缓解时,可考虑加用诺乙雄龙维持治疗以改善生存。
- 基线白细胞>30×10^9/L的患者未从诺乙雄龙获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Elderly patients with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could improve their outcomes. Androgens, used in the treatment of aplastic anemia, have been reported to block proliferation of and initiate differentiation in AML cells. We report the results of a multicenter, phase III, randomized open-label trial exploring the benefit of adding androgens to maintenance therapy in patients 60 years of age or older. Patients and Methods A total of 330 patients with AML de novo or secondary to chemotherapy or radiotherapy were enrolled in the study. Induction therapy included idarubicin 8 mg/m2 on days 1 to 5, cytarabine 100 mg/m2 on days 1 to 7, and lomustine 200 mg/m2 on day 1. Patients in complete remission or partial remission received six reinduction courses, alternating idarubicin 8 mg/m2 on day 1, cytarabine 100 mg/m2 on days 1 to 5, and a regimen of methotrexate and mercaptopurine. Patients were randomly assigned to receive norethandrolone 10 or 20 mg/day, according to body weight, or no norethandrolone for a 2-year maintenance therapy regimen. The primary end point was disease-free survival by intention to treat. Secondary end points were event-free survival, overall survival, and safety. This trial was registered at www.ClinicalTrials.gov identifier NCT00700544. Results Random assignment allotted 165 patients to each arm; arm A received norethandrolone, and arm B did not receive norethandrolone. Complete remission or partial remission was achieved in 247 patients (76%). The Schoenfeld time-dependent model showed that norethandrolone significantly improved survival for patients still in remission at 1 year after induction. In arms A and B, respectively, 5-year disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall survival was 26.3% and 17.2%. Norethandrolone improved outcomes irrelevant to all prognosis factors. Only patients with baseline leukocytes > 30 × 109/L did not benefit from norethandrolone. Conclusion This study demonstrates that maintenance therapy with norethandrolone significantly improves survival in elderly patients with AML without increasing toxicity.
引用
- Pigneux A, Béné MC, Guardiola P, et al. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. J Clin Oncol. 2016. PMID: 28129526. doi:10.1200/JCO.2016.67.6213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。